With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its ...

Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief ...

Synthetic biology specialist GRO Biosciences is exploring strategic alternatives about six months after raising a series B ...

The National Institutes of Health (NIH) is continuing its grant-canceling spree, allegedly targeting dozens of research ...

The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...